PARP inhibitors in prostate cancer: time to narrow patient selection?

Mark C. Markowski, Emmanuel S. Antonarakis

Research output: Contribution to journalEditorialpeer-review

4 Scopus citations
Original languageEnglish (US)
Pages (from-to)523-526
Number of pages4
JournalExpert Review of Anticancer Therapy
DOIs
StatePublished - 2020
Externally publishedYes

Bibliographical note

Funding Information:
This work was partially supported by National Institutes of Health Cancer Center Support Grant P30CA006973 (E.S.A.) and a Prostate Cancer Foundation Young Investigator Award (M.C.M).

Keywords

  • PARP inhibitors
  • metastatic castration-resistant prostate cancer
  • niraparib
  • olaparib
  • prostate cancer
  • rucaparib
  • talazoparib

Cite this